Novo Nordisk Reports Q3 2024 Results: Semaglutide Surpasses $20 Billion in Sales
Novo Nordisk
Insulin Developer and Manufacturer
On November 6, 2024, Novo Nordisk announced its Q3 2024 performance, with year-to-date revenue for the first three quarters204.72 billion Danish kroner (29.46 billion US dollars), a year-on-year increase of 24%(Calculated at fixed exchange rates, same below); Operating Profit91.602 billion Danish kroner, an increase of 22% year-on-year; net profit72.758 billion Danish kroner。
Sales in the diabetes and obesity care business have grown 25%(DKK billion) to DKK 191.8 billion,Mainly due toGLP-1 (including semaglutide, liraglutide) diabetes sales increased by 25%, and obesity care business sales grew by 44%, reaching106.95 billion Danish kronerAnd43.7 billion Danish kronerSales of rare disease products increased by 3% to DKK 12.934 billion.
It is worth mentioning that,Weight-Loss Version of SemaglutideWegovy Climbed toDKK 17.3 billion (USD 2.5 billion)，Higher than the average analyst expectation of 15.6 billion Danish kroner.The first three quartersSemaglutide hasTotal Revenue1412.13Million Danish Kroner(approximately$20.3 billion），SuperpositionNovo Nordisk's strong capacity expansion and continuous output surpass K drug (first three quarters)$21.6 billion) Only half a step away.
Moreover, Novo Nordisk narrowed its full-year sales and profit forecast.For the full-year sales in 2024, Novo Nordisk expects a growth rate of23%-27%(The previously forecasted growth rate was 22% to 28%), while the operating profit growth rate is21%-27%(The previously predicted growth rate was 20% to 28%).
01
Revenue from Key Products in the First Three Quarters
In terms of products,Semaglutide revenue increased by 43% year-on-year to DKK 141.213 billion (approximately USD 20.3 billion), accounting for the group's total revenue.69%. Among them:
Sales of Semaglutide (Hypoglycemic Injection Version) Ozempic86.489 billion Danish kroner, year-on-year growth32%；
Sales of Semaglutide (Oral Version for Blood Sugar Control) Rybelsus163.84DKK billion, a year-on-year increase of 29%;
Sales of Semaglutide (Weight Loss Injectable Version) Wegovy383.40DKK billion, a year-on-year increase of 77%.
Ozempic (glycemic control injectable version) sales reached 4.747 billion Danish kroner, representing a year-on-year increase of 28%. Rybelsus (oral version for blood sugar control) sales reached 151 million Danish kroner, a year-on-year increase of 64%;
02
Key Product Progress in Q3
In 2024 Q3, Novo Nordisk achieved more results in the development of products such as semaglutide, including the SOUL trial for patients with diabetes and cardiovascular diseases and the ESSENCE trial for patients with MASH.
9Month20Day, Novo Nordisk has completedmonlunabant（INV-202) For the treatment of obesity 2a Phase trial is expected to 2025 Launched a larger-scale obesity 2b Phase Trial, to Further StudymonlunabantLonger-term dosing and safety in global populations.Monlunabantis a small molecule oral CB1 Receptor inverse agonist, used for the treatment of obesity and metabolic syndrome.The drug is from Novo Nordisk in2023Year8Monthly Acquisition Inversago Pharmaceuticals Through transactions.
In the field of diabetes, 10Month21Date: Novo Nordisk announcedSOULMain results of the cardiovascular outcomes trial:GLP-1Receptor AgonistOral SemaglutideSignificantly Reduce2Type 2 Diabetes Mellitus with Cardiovascular Disease (CVD) and/Or chronic kidney disease (CKD) Cardiovascular risk in patients14%。
Also in October, a study showed that Ozempic could reduce the risk of Alzheimer's disease.The Risk , indicating its potential to delay or prevent this memory loss disease.
11Month1Day,Novo Nordisk also announcedESSENCEThe important results of the trial, in patients withMASHUsed in adult patients with liver fibrosis2.4mgThesemaglutide，The results showed that, compared with placebo,WegovyImproving liver fibrosis without exacerbating steatohepatitis, and achieving the regression of steatohepatitis without worsening liver fibrosis.
References:
Company Official Website
Disclaimer
1. All information provided by the "Drug Hunter Club" is for reference only and should not be used as a basis for any commercial transactions or medical services. If there are any discrepancies arising from the independent use of the content from the "Drug Hunter Club," our company assumes no responsibility, including but not limited to legal liability or compensation.
2. "Drug Hunter Club" is committed to providing reasonable, accurate, and complete information, but does not guarantee the reasonableness, accuracy, or completeness of the information, and assumes no responsibility for any loss or damage caused by unreasonable, inaccurate, or omitted information.
3. Some article information in the "Drug Hunter Club" is sourced from online reprints, aimed at sharing more information, and does not imply endorsement of the viewpoints or confirmation of the authenticity of the content. If you have any questions about the content, please contact our company promptly.
4. For issues not covered in this statement, please refer to relevant national laws and regulations. In case of any conflict between this statement and national laws and regulations, the latter shall prevail.
